论文部分内容阅读
[目的]观察结核丸联合2HRZE/4HR方案治疗初患涂阳肺结核疗效。[方法]使用随机平行对照方法,将住院患者按病志号抽签方法简单随机分为两组。对照组55例2HRZE/4HR方案:异烟肼0.3g/次,1次/d,口服;利福平0.45g/次,1次/d,口服;乙胺丁醇0.75g/次,1次/d,口服;吡嗪酰胺0.5g/次,3次/d,口服。治疗组55例结核丸3.5g/次,2次/d,口服;2HRZE/4HR方案治疗同对照组。连续治疗6个月为1疗程。观测临床症状、痰菌、病灶、满意度、不良反应。治疗1疗程(2个月),判定疗效。随访2个月。[结果]临床症状、痰菌阴转、病灶吸收两组间无明显差异(P>0.05)。满意度治疗组优于对照组(P<0.05)。随访2个月,临床症状、痰菌阴转、病灶吸收两组间无明显差异(P>0.05)。[结论]结核丸联合2HRZE/4HR方案,与单纯西药治疗无显著差异,应进一步扩大研究样本。
[Objective] To observe the curative effect of tuberculin and 2HRZE / 4HR in the treatment of smear-positive pulmonary tuberculosis. [Methods] Randomized parallel control method was used to randomly divide hospitalized patients into two groups randomly according to the method of lot drawing of disease symbols. Control group of 55 cases of 2HRZE / 4HR program: isoniazid 0.3g / times, 1 time / d, oral; rifampicin 0.45g / times, 1 time / d, oral; ethambutol 0.75g / time, 1 / d, oral; pyrazinamide 0.5g / times, 3 times / d, orally. 55 cases of tuberculosis treatment group 3.5g / time, 2 times / d, oral; 2HRZE / 4HR treatment with the control group. Continuous treatment of 6 months for a course of treatment. Observation of clinical symptoms, sputum bacteria, lesions, satisfaction, adverse reactions. Treatment 1 course of treatment (2 months), determine the efficacy. Follow up for 2 months. [Results] There were no significant differences in clinical symptoms, sputum negative conversion and lesion absorption between the two groups (P> 0.05). Satisfaction in treatment group was better than that in control group (P <0.05). After 2 months of follow-up, there were no significant differences in clinical symptoms, sputum negative conversion and lesion absorption between the two groups (P> 0.05). [Conclusion] The combination of tuberculosis pills and 2HRZE / 4HR regimen has no significant difference with western medicine alone. The study sample should be further expanded.